Want to see RANI full AI Analyst Report?
RANI Stock Chart & Stats
$0.96
-$0.04(-3.15%)
At close: 4:00 PM EST
$0.96
-$0.04(-3.15%)
Day’s Range― - ―
52-Week Range$0.40 - $3.87
Previous CloseN/A
Volume228.85K
Average Volume (3M)693.99K
Market Cap
$95.08M
Enterprise Value$99.74
Total Cash (Recent Filing)$43.40M
Total Debt (Recent Filing)$3.94M
Price to Earnings (P/E)―
Beta2.56
Next Earnings
Aug 06, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding112,389,150
10 Day Avg. Volume905,953
30 Day Avg. Volume693,986
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.70
Price to Sales (P/S)54.68
P/FCF Ratio-4.75
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.50Price Target Upside681.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.18
Revenue Forecast (FY)$2.42M
Bulls Say, Bears Say
Bulls Say
Platform PartnershipsThe RaniPill platform continues to attract external partners (PegBio, ProGen/Chugai collaborations noted). Multiple collaborations expand the addressable pipeline, diversify milestone/royalty opportunity streams, and validate platform utility—supporting a durable licensing and partner-funded development model.
High Gross MarginA reported TTM gross margin near 72% indicates the core delivery technology can produce attractive product-level economics. If clinical programs scale or partners commercialize, high gross margins support sustainable unit economics for licensing and royalties, improving long-term profitability potential once fixed R&D costs are amortized.
Lower LeverageBalance-sheet leverage is modest versus prior periods (debt-to-equity ~0.14) and equity is positive, reducing near-term solvency pressure. Manageable leverage enhances funding optionality, lowers bankruptcy risk and supports continued investment in clinical development and partnership programs over the medium term.
Bears Say
Tiny, Declining RevenueRevenue remains very small and declined year-over-year, reflecting absence of commercial products and reliance on episodic collaboration payments. This limited revenue base cannot cover fixed operating costs, making the company dependent on successful partner milestones and external funding to sustain operations and scale the business model.
Persistent Cash BurnMaterial negative operating and free cash flow indicate ongoing cash consumption to fund trials and development. Continued burn constrains strategic flexibility, necessitates recurrent capital raises or partnerships, and increases dilution risk—structural pressures until revenue from partners or product commercialization becomes meaningful.
Nasdaq Listing Risk / Management TransitionA Nasdaq bid-price noncompliance notice creates structural listing and investor-access risk that can force corporate actions (reverse split or transfer) and distract management. Coupled with a CFO transition, this raises execution and capital-raising uncertainty and can increase the company’s cost of capital over the medium term.
Rani Therapeutics Holdings News
RANI FAQ
What was Rani Therapeutics Holdings, Inc. Class A’s price range in the past 12 months?
Rani Therapeutics Holdings, Inc. Class A lowest stock price was $0.40 and its highest was $3.87 in the past 12 months.
What is Rani Therapeutics Holdings, Inc. Class A’s market cap?
Rani Therapeutics Holdings, Inc. Class A’s market cap is $95.08M.
When is Rani Therapeutics Holdings, Inc. Class A’s upcoming earnings report date?
Rani Therapeutics Holdings, Inc. Class A’s upcoming earnings report date is Aug 06, 2026 which is in 17 days.
How were Rani Therapeutics Holdings, Inc. Class A’s earnings last quarter?
Rani Therapeutics Holdings, Inc. Class A released its earnings results on May 15, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.045 by $0.005.
Is Rani Therapeutics Holdings, Inc. Class A overvalued?
According to Wall Street analysts Rani Therapeutics Holdings, Inc. Class A’s price is currently Undervalued.
Does Rani Therapeutics Holdings, Inc. Class A pay dividends?
Rani Therapeutics Holdings, Inc. Class A does not currently pay dividends.
What is Rani Therapeutics Holdings, Inc. Class A’s EPS estimate?
Rani Therapeutics Holdings, Inc. Class A’s EPS estimate is -0.05.
How many shares outstanding does Rani Therapeutics Holdings, Inc. Class A have?
Rani Therapeutics Holdings, Inc. Class A has 112,389,150 shares outstanding.
What happened to Rani Therapeutics Holdings, Inc. Class A’s price movement after its last earnings report?
Rani Therapeutics Holdings, Inc. Class A reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.045. Following the earnings report the stock price went down -10%.
Which hedge fund is a major shareholder of Rani Therapeutics Holdings, Inc. Class A?
Currently, no hedge funds are holding shares in RANI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rani Therapeutics Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.50 (681.25% Upside)
$7.50 (681.25% Upside)
Blogger Sentiment
Bullish
RANI Sentiment 100%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
67.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
115.04%
Trailing 12-Months
Company Description
Rani Therapeutics Holdings, Inc. Class A
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
RANI Stock 12 Month Forecast
Average Price Target
$7.50
▲(681.25% Upside)
Technical Analysis
Ownership Overview
24.70% Insiders
4.85% Mutual Funds
0.03% Other Institutional Investors
66.29% Public Companies and
Individual Investors